// App-Quantinova.ai

9016 : Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

Researchers

Presenter

  • Shirish M. Gadgeel

Principal Investigators

  • James Stevenson

  • Corey J. Langer

  • Leena Gandhi

  • Hossein Borghaei

  • Amita Patnaik

  • Liza Cosca Villaruz

  • Matthew A. Gubens

  • Ralph J. Hauke

  • James Chih-Hsin Yang

  • Lecia V. Sequist

  • Robert D. Bachman

  • Joy Yang Ge

  • Harry Raftopoulos

  • Vassiliki Papadimitrakopoulou

Medical Centers

  • Karmanos Cancer Institute, Detroit, MI

  • Cleveland Clinic Foundation, Cleveland, OH

  • University of Pennsylvania, Abramson Cancer Center, Philadelphia, PA

  • Dana-Farber Cancer Institute, Boston, MA

  • Fox Chase Cancer Center, Philadelphia, PA

  • START-South Texas Accelerated Research Therapeutics, LLC, San Antonio, TX

  • University of Pittsburgh Cancer Institute, Pittsburgh, PA

  • University of California, San Francisco, San Francisco, CA

  • Nebraska Cancer Specialists, Omaha, NE

  • National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan

  • Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA

  • Merck & Co., Inc., Kenilworth, NJ

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

Locations

  • United States

  • Taiwan

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Anaplastic lymphoma Kinase

  • Cancer antigen 15-3

  • Epidermal growth factor receptor

Drug/Treatment

  • Pembrolizumab

  • Bevacizumab

  • Carboplatin

  • Paclitaxel

  • Pemetrexed

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT02039674

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved